HIM
XLRN

Hillhouse Investment Management’s Acceleron Pharma XLRN Stock Holding History

Hillhouse Investment Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-813,600
Closed -$46.6M – 45
2018
Q3 		$46.6M Buy
813,600
+113,600
+16% +$5.58M 1.24% 20
2018
Q2 		$34M Hold
700,000
– – 0.58% 27
2018
Q1 		$27.4M Hold
700,000
– – 0.48% 26
2017
Q4 		$29.7M Hold
700,000
– – 0.5% 21
2017
Q3 		$26.1M Hold
700,000
– – 0.43% 22
2017
Q2 		$21.3M Hold
700,000
– – 0.33% 23
2017
Q1 		$18.5M Buy
700,000
+200,000
+40% +$5.27M 0.36% 21
2016
Q4 		$12.8M Buy
500,000
+200,000
+67% +$6.34M 0.28% 18
2016
Q3 		$10.9M Buy
+300,000
New +$9.94M 0.22% 21

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Hillhouse Investment Management's XLRN Position: Q4 2018 in Review

Hillhouse Investment Management sold out of Acceleron Pharma (XLRN) in Q4 2018, closing a stake of 813,600 shares — an estimated $46.6M sold.

Hillhouse Investment Management first reported a position in XLRN in Q3 2016 and held it in 9 quarters. The position peaked at $46.6M in Q3 2018. 162 funds tracked by Wall St. Rank hold XLRN as of Q4 2018.

  • Hillhouse Investment Management reported no remaining Acceleron Pharma position as of Q4 2018 after selling out during the quarter.
  • Hillhouse Investment Management sold 813,600 Acceleron Pharma shares in Q4 2018, an estimated $46.6M.
  • Hillhouse Investment Management first reported a position in Acceleron Pharma in Q3 2016 and held it in 9 quarters.
  • Hillhouse Investment Management's Acceleron Pharma position peaked at $46.6M in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2018.

Based on Hillhouse Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.